Interferon-alpha in Childhood Haematological Malignancies

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 1996 Dec 1

PMID 9015462

Authors

R Simko

K Nagy

Affiliations

Soon will be listed here.

Abstract

The application of cytostatics has brought about a breakthrough in the treatment of childhood haematological malignancies in the past 20 years. Chemotherapy appears to be least successful in the rare, low and very high mitotic index diseases, which often have an enormous tumour-burden. The suitability of chemotherapy in minimal residual leukaemia is also of some doubt. In these situations a 'conservative' treatment may be more appropriate. Because interferon-alpha has a distinct mechanism of action, and a broad-spectrum haematopoietic inhibitory activity, it is relatively nontoxic and noncancerogenic, and it may have a role in the treatment of malignant haematological disorders, either as a mono- or combination therapy. The exact indications and dosages for interferon in childhood malignancies are far from clear. Up to now, it has proved to be most efficacious in small tumour masses, providing a theoretical basis for application in minimal residual disease. Controlled clinical data, however, are not yet available. It remains to be determined whether or not interferon can be added to current chemotherapy protocols without a significant reduction of dose. Hopefully, a deeper understanding of the activities of interferon will allow us to plan better trials with combination treatments.

References

Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H . Interferon therapy in myelomatosis. Lancet. 1979; 1(8110):245-7. DOI: 10.1016/s0140-6736(79)90770-0. View

Dow L, Raimondi S, Culbert S, Ochs J, Kennedy W, Pinkel D . Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer. 1991; 68(8):1678-84. DOI: 10.1002/1097-0142(19911015)68:8<1678::aid-cncr2820680803>3.0.co;2-j. View

Greenberger J, Crocker A, VAWTER G, Jaffe N, Cassady J . Results of treatment of 127 patients with systemic histiocytosis. Medicine (Baltimore). 1981; 60(5):311-38. DOI: 10.1097/00005792-198109000-00001. View

Castro-Malaspina H, Schaison G, Passe S, Pasquier A, Berger R, Miller D . Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors. Cancer. 1984; 54(4):675-86. DOI: 10.1002/1097-0142(1984)54:4<675::aid-cncr2820540415>3.0.co;2-q. View

Bunn Jr P, Foon K, Ihde D, Longo D, Eddy J, Winkler C . Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984; 101(4):484-7. DOI: 10.7326/0003-4819-101-4-484. View

Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K . Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia. 1991; 5(10):892-5. View

Klingemann H, Grigg A, Barnett M, Eaves A, Reece D, Shepherd J . Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood. 1991; 78(12):3306-11. View

Talpaz M, Kantarjian H, Kurzrock R, Gutterman J . Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer. 1992; 69(2):410-2. DOI: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. View

Tolaymat A, LEVENTHAL B, Sakarcan A, Kashima H, Monteiro C . Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr. 1992; 120(3):429-32. DOI: 10.1016/s0022-3476(05)80913-8. View

10.

Sen G, Lengyel P . The interferon system. A bird's eye view of its biochemistry. J Biol Chem. 1992; 267(8):5017-20. View

11.

Grander D, Heyman M, Brondum-Nielsen K, Liu Y, Lundgren E, Soderhall S . Interferon system in primary acute lymphocytic leukemia cells with or without deletions of the alpha-/beta-interferon genes. Blood. 1992; 79(8):2076-83. View

12.

Kantarjian H, Keating M, Estey E, OBrien S, Pierce S, Beran M . Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992; 10(5):772-8. DOI: 10.1200/JCO.1992.10.5.772. View

13.

Pechumer H, Walther J, Klingebiel T, Ehninger G, Suttorp M, Schmitz N . [Juvenile chronic leukemia and chronic myelomonocytic leukemia. Experiences with bone marrow transplantation in childhood in 5 cases]. Monatsschr Kinderheilkd. 1992; 140(5):307-12. View

14.

Marin T, Butturini A, Kantarjian H, Sokal J, Mickey M, Gale R . Survival of children with chronic myeloid leukemia. Am J Pediatr Hematol Oncol. 1992; 14(3):229-32. DOI: 10.1097/00043426-199208000-00008. View

15.

Halton J, Whitton A, Wiernikowski J, Barr R . Disseminated Langerhans cell histiocytosis in identical twins unresponsive to recombinant human alpha-interferon and total body irradiation. Am J Pediatr Hematol Oncol. 1992; 14(3):269-72. DOI: 10.1097/00043426-199208000-00016. View

16.

Trapani J, Browne K, Dawson M, Ramsay R, Eddy R, Show T . A novel gene constitutively expressed in human lymphoid cells is inducible with interferon-gamma in myeloid cells. Immunogenetics. 1992; 36(6):369-76. DOI: 10.1007/BF00218044. View

17.

Hazani A, Barak Y, Berant M, BAR-MAOR A . Congenital juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha-2. Med Pediatr Oncol. 1993; 21(1):73-6. DOI: 10.1002/mpo.2950210115. View

18.

Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M . Chronic myelogenous leukemia: a concise update. Blood. 1993; 82(3):691-703. View

19.

Bockenstedt P, Santinga J, Bolling S . alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol. 1994; 45(3):248-51. DOI: 10.1002/ajh.2830450311. View

20.

Miller V, Zwiener R, Fielman B . Interferon-associated refractory status epilepticus. Pediatrics. 1994; 93(3):511-2. View